How much does durvalumab (durvalumab) cost? Latest market price analysis

Durvalumab (Durvalumab), the Chinese trade name is durvalumab, is a PD-L1 inhibitor and belongs to the immune checkpoint inhibitor class of drugs. It has been approved for marketing in China and is mainly used to treat unresectable non-small cell lung cancer (NSCLC) and other specific types of cancer. Although the drug has been marketed in China, it has not yet been included in the national medical insurance directory, so patients still have to bear higher costs when purchasing the drug out of pocket.

In the domestic market, the common specifications of durvalumab are120mg/2.4mL and 500mg/10mLTwo kinds, the price of each box may range from 4000 to more than 10,000 yuan. The specific selling price is also affected by factors such as different hospitals or pharmacies’ purchase channels, regional differences and other factors. Since the drug is an imported original drug and there has been no price negotiation to lower the threshold, its overall selling price is high, which to a certain extent puts pressure on patients' financial affordability.

In overseas markets, durvalumab is also available, especially in Europe and the United States, and the price is still not low. Taking the 120mg/2.4mL specification as an example, each box is priced at about 1,000 more than US dollars, which is equivalent to about seven to eight thousand yuan in RMB. The specific price will be adjusted with exchange rate fluctuations. While some patients may choose to obtain the drug through Hong Kong or other international pharmacies, import procedures and transportation costs may also increase final drug purchase expenses.

It is worth noting that as of now, there are no generic versions of durvalumab on the market, which also means that there are fewer alternatives on the market. For some patients with limited financial conditions, whether they can use the drug through clinical trials, charitable drug donation programs, or waiting for the results of medical insurance negotiations will become an important factor in deciding whether to use the drug long-term. If there are generic versions or adjustments to medical insurance policies in the future, the accessibility of durvalumab may be greatly improved.

Reference materials:https://www.imfinzi.com/